Core Viewpoint - Medline Inc. completed a $6.26 billion IPO, marking the largest IPO in the U.S. stock market in four years and the fifth largest in the past decade, with a post-IPO valuation exceeding $66 billion, nearly double its valuation during the private equity acquisition four years ago [1][5][8]. Group 1: IPO Details - Medline's IPO involved the sale of 216 million shares at an initial price of $29, which was close to the upper limit of the pricing range, and the stock opened at $35, reflecting a nearly 21% increase [3][6]. - The IPO was oversubscribed by more than ten times, leading to an increase in the number of shares offered from an initial plan of 179 million [6]. - The successful IPO raised optimism for the 2026 IPO market, potentially setting the stage for significant upcoming listings, including SpaceX [5][12]. Group 2: Financial Performance - For the nine months ending September 27, Medline reported a net income of $977 million and revenue of $20.6 billion, compared to a net income of $911 million and revenue of $18.7 billion in the same period the previous year [9]. - The company anticipates a total net sales figure of $25.5 billion for the full year of 2024 [9]. Group 3: Company Background and Strategy - Medline, founded in 1966, manufactures and distributes medical supplies, serving hospitals and clinics with a product range of approximately 335,000 surgical items [8]. - The company aims to position itself as the "Costco of healthcare," focusing on a strong supply chain and proprietary products while gradually replacing third-party products [9]. - Following a significant private equity acquisition in 2021, Medline's valuation has seen substantial growth, with the IPO reflecting a valuation of around $39 billion at the issuance price and approximately $47 billion at the opening price [8][10]. Group 4: Market Context and Future Outlook - The IPO market in the U.S. saw a total fundraising amount exceeding $46 billion in 2025, despite challenges such as government shutdowns and tariff uncertainties affecting the market [12]. - Medline's IPO is expected to encourage more private equity firms to take their portfolio companies public in the near future, with several anticipated IPOs in 2026 [12].

Core Viewpoint - Medline Inc. successfully completed a $6.26 billion IPO, marking the largest IPO globally in 2025 and receiving strong investor interest on its first trading day [1][3][6]. Group 1: IPO Details - Medline debuted on NASDAQ under the ticker MDLN, opening at $35, a nearly 21% increase from the $29 issue price, and closing at $41, a 41.4% rise [3][6]. - The company sold 216 million shares, with the final pricing near the upper end of the guidance range, resulting in a post-IPO valuation exceeding $66 billion [6][7]. - Medline's IPO surpassed the previous record held by CATL's $5.26 billion listing, making it the largest IPO since Rivian's $13.7 billion in 2021 and the fifth largest in the past decade in the U.S. [6][12]. Group 2: Investor Interest and Backing - The IPO was over 10 times oversubscribed, leading to an increase in the number of shares offered from an initial plan of 179 million [7]. - Medline secured $2.35 billion in commitments from cornerstone investors, including Baillie Gifford and Morgan Stanley's Counterpoint Global [7][8]. - The company allocated over 3.7 million shares from the IPO proceeds to repurchase stock from pre-IPO shareholders, allowing private equity firms to realize returns without directly selling shares [7][8]. Group 3: Company Background and Performance - Founded in 1966, Medline manufactures and distributes medical supplies, serving hospitals and clinics with a product range of approximately 335,000 items [8][9]. - The company reported a net income of $977 million and revenue of $20.6 billion for the nine months ending September 27, with a projected annual revenue of $25.5 billion for 2024 [9][11]. - Medline aims to position itself as the "Costco of healthcare," focusing on a strong supply chain and proprietary products [9]. Group 4: Challenges and Strategic Moves - Medline faced challenges in its IPO journey due to uncertainties from tariff policies and government shutdowns, which delayed its initial plans [10][12]. - The company anticipates a pre-tax income loss of $150 million to $200 million due to tariffs in fiscal year 2026 [11]. - Strategic investments have been made under new leadership, including a $905 million acquisition of Ecolab's surgical solutions business and $1.6 billion in capital expenditures over the past five years [11]. Group 5: Market Outlook - Medline's successful IPO has positively influenced market sentiment for future IPOs in 2026, with expectations for significant listings such as SpaceX [6][12]. - The overall IPO market in the U.S. for 2025 exceeded $46 billion, despite challenges faced earlier in the year [12][13].

Core Insights - Medline Inc. completed a $6.26 billion IPO, marking the largest global IPO of 2025 and receiving strong investor interest on its first trading day [1][3] Group 1: IPO Details - Medline's stock debuted on NASDAQ under the ticker MDLN at an opening price of $35, a nearly 21% increase from the $29 issue price, reaching over $38 during trading, with a peak increase of over 30% [3] - The IPO involved the sale of 216 million shares, with the opening valuation of Medline reaching $47 billion, approximately 40% higher than its valuation during a 2021 acquisition by private equity firms [3][6] - This IPO surpassed the previous record held by CATL's $5.26 billion listing, making it the largest IPO of the year and the largest in the U.S. since Rivian's $13.7 billion IPO in 2021 [3][6] Group 2: Market Impact - Medline's successful IPO contributed to a total IPO fundraising exceeding $46 billion for the year, boosting optimism for the 2026 IPO market, potentially setting the stage for significant listings like SpaceX [4][10] - The IPO received over 10 times the subscription demand, leading to an increase in the number of shares issued from an initial plan of 179 million to 216 million [5] Group 3: Company Background - Medline, founded in 1966, specializes in manufacturing and distributing medical supplies, serving hospitals and clinics with a product range of approximately 335,000 items [6] - The company was acquired by private equity firms Blackstone, Carlyle Group, and Hellman & Friedman in 2021 for up to $34 billion, marking one of the largest leveraged buyouts in history [6] - Medline's CEO, Jim Boyle, aims to position the company as the "Costco of healthcare," emphasizing a strong supply chain and a loyal customer base [7] Group 4: Financial Performance - For the nine months ending September 27, Medline reported a net income of $977 million and revenue of $20.6 billion, compared to $911 million and $18.7 billion in the same period the previous year [7] - The company anticipates a total revenue of $25.5 billion for the full year of 2024 [7] Group 5: Challenges and Strategic Moves - Medline faced challenges in its IPO journey due to uncertainties from U.S. tariff policies and a government shutdown, which delayed its initial plans for a mid-2023 listing [8] - The company has made strategic investments, including a $905 million acquisition of Ecolab Inc.'s surgical solutions business and $1.6 billion in capital expenditures over the past five years to enhance its distribution network [9]

Core Viewpoint - Medline Inc. has successfully completed the largest IPO in the U.S. this year, raising $6.26 billion with a final pricing of $29 per share for 216 million shares, leading to a market valuation of approximately $39 billion [1][2]. Group 1: IPO Details - The IPO is set to officially launch on the Nasdaq under the ticker "MDLN" on December 17, 2025, after an increase in the offering size [1]. - Medline's IPO fundraising exceeds that of the largest global IPO this year, which was $5.26 billion by Chinese battery manufacturer CATL, and also surpasses the $1.75 billion raised by Venture Global in January [2]. - This transaction marks the largest majority stake IPO ever executed by a private equity-controlled company, surpassing the $5.1 billion IPO of Lineage Inc. last year [2]. Group 2: Company Background - Medline was founded in 1966 by Jon Mills and Jim Mills, with the Mills family remaining the largest individual shareholders post-IPO, holding 17.8% of the voting rights [4]. - The company produces and distributes medical supplies used by hospitals and physicians, offering approximately 335,000 surgical products and achieving next-day delivery to 95% of U.S. customers [4]. - As of September 27, the company reported revenues of $20.6 billion and a net profit of $977 million for the nine months, compared to $18.7 billion in revenue and $911 million in net profit during the same period last year [4]. Group 3: Shareholder Composition - Major shareholders include private equity giants Blackstone, Carlyle Group, and Hellman & Friedman, each holding 18% of the voting rights after the transaction [4]. - The Mills family and affiliates have expressed interest in purchasing up to $250 million worth of stock in the IPO [4]. Group 4: Market Context - Over the past decade, only five companies have raised more than $5 billion in IPOs in the U.S., with Medline's $6.26 billion placing it among them, alongside Uber, Lineage, Rivian Automotive, and Arm Holdings [3]. - The total IPO fundraising in the U.S. (excluding SPACs) has exceeded $46 billion this year, although it remains slightly below the pre-pandemic average of nearly $50 billion per year [3].